TPI Schedules Test Runs at Jiangchuan Macrolide Facility by End of July

^{Published on 2011-07-08 04:10:44 - Market Wire}
 

TPI Schedules Test Runs at Jiangchuan Macrolide Facility by End of July -- CHENGDU, China, July 8, 2011 /PRNewswire-Asia-FirstCall/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about TPI

CHENGDU, China, July 8, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: [ TPI ]), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today announced that its 250-ton Jiangchuan Macrolide facility (JCM) is scheduled for its manufacturing test runs by the end of July.

The test runs prepare the production lines for the final Good Manufacturing Practice (GMP) certification process by conducting a series of operations and tests under actual or simulated operating conditions to verify its performance, efficiency, reliability and safety of the Azithromycin API manufacturing at JCM.

The successful completion of the test runs will be immediately followed by the GMP certification at JCM.

About GMP

Good Manufacturing Practice (GMP), widely adopted worldwide, provide guidelines covering the manufacture and testing of pharmaceuticals and active pharmaceutical ingredients, diagnostics, foods, pharmaceutical products, and medical devices with the basic concepts that safeguard the health of the patient, producing a good quality medicine, medical devices or active pharmaceutical products. GMP guidelines are a series of general principles that are mandated during manufacturing. The context of GMP covers plant and equipment operation, personnel training, quality management, product safety and stability along with other aspects that ensure the quality the product ([ www.sfda.gov.cn ], Chinese version).

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit: [ http://www.tianyinpharma.com ].

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

SOURCE Tianyin Pharmaceutical Co., Inc.

RELATED LINKS
[ http://www.tianyinpharma.com ]
[ http://www.sfda.gov.cn ]